サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1405892

前立腺がん診断の市場規模、シェア、動向分析レポート：検査タイプ別、タイプ別、最終用途別、地域別、セグメント予測、2024年～2030年

Prostate Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Preliminary Tests, Confirmatory Tests), By Type (Adenocarcinoma, Interstitial Cell Carcinoma, Other), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 152 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
前立腺がん診断の市場規模、シェア、動向分析レポート：検査タイプ別、タイプ別、最終用途別、地域別、セグメント予測、2024年～2030年
出版日: 2023年12月22日
発行: Grand View Research
ページ情報: 英文 152 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

前立腺がん診断市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の前立腺がん診断市場規模は、2024年から2030年にかけてCAGR 6.4％で拡大し、2030年には131億6,000万米ドルに達すると予測されています。

政府の支援策、世界の疾患有病率の増加、前立腺がんの有病率の上昇と確定診断検査の技術的進歩がこの市場の主な促進要因です。

効果的な診断と治療に焦点を当てた研究を強化するための有利な政府のイニシアチブの増加は、予測期間中の市場成長を促進すると予想されます。例えば、国立がん研究所は、「アフリカ系男性の前立腺がんに関する調査」と題する研究を開始した：遺伝学、腫瘍マーカー、社会的ストレスの役割の定義」（RESPOND）です。この調査は、アフリカ系アメリカ人男性の前立腺がんに関連する非生物学的および生物学的因子を調査する最大の共同研究です。米国国立少数民族健康研究所（National Institute on Minority Health and NCI and Health Disparities）が前立腺がん財団（Prostate Cancer Foundation）と共同で2,600万米ドルの資金を得て開始しました。

ノーフォーク大学およびイースト・アングリアの研究開発とノリッチ大学病院は、診断から5年以内に治療処置が必要になる可能性が最大8倍低い男性を特定するのに役立つ非侵襲的尿検査を開発しました。このような技術の進歩は、近い将来、市場の可能性にも影響を与えると予想されます。

さらに、カロリンスカ研究所とKTH研究所の研究者らは、空間トランスクリプトミクスに人工知能を用いることで、前立腺がんの早期発見に役立ち、それによって臨床診断と治療が改善されると結論づけた。空間トランスクリプトミクスは、通常、活性遺伝子とその組織像の定量分析を組み合わせた手法であり、効果的な疾患診断に役立ちます。

前立腺がん診断市場レポートハイライト

  • 2023年の市場シェアは確認検査が最大。このセグメントは66.4%で最大の市場シェアを占めています。確認検査には、PCA3検査、経直腸超音波検査（TRUS）、患部の生検が含まれます。
  • 最終用途に基づき、市場は病院、外来患者施設、在宅医療、研究・製造に区分されます。2023年には、外来患者施設セグメントが市場を独占しました。外来施設は、医師免許を取得し経験を積むことで、より快適なコンサルティングと治療システムを革命的に開発しました。
  • 北米地域が最大の市場シェアを占めているのは、有病率の上昇と診断強化のための政府イニシアチブの高まりによるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 前立腺がん診断市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 前立腺がん診断市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 前立腺がん診断市場：検査タイプの推定・動向分析

  • 検査タイプの市場シェア、2023年および2030年
  • セグメントダッシュボード
  • 検査タイプ別の世界の前立腺がん診断市場の見通し
  • 以下の市場規模、予測および動向分析、2018年～2030年
    • 予備テスト
    • 確認検査

第5章 前立腺がん診断市場：タイプの推定・動向分析

  • タイプ市場シェア、2023年および2030年
  • セグメントダッシュボード
  • タイプ別の前立腺がん診断市場の世界展望
  • 以下の市場規模、予測および動向分析、2018年～2030年
    • 腺がん
    • 間質細胞がん
    • その他

第6章 前立腺がん診断市場：最終用途推定・動向分析

  • 最終用途市場シェア、2023年および2030年
  • セグメントダッシュボード
  • 最終用途別の世界の前立腺がん診断市場の見通し
  • 以下の市場規模、予測および動向分析、2018年～2030年
    • 病院
    • 外来施設
    • ホームケア
    • 研究・製造

第7章 前立腺がん診断市場：地域推定・動向分析

  • 地域市場シェア分析、2023年および2030年
  • 地域市場ダッシュボード
  • 世界の地域市場のスナップショット
  • 市場規模と予測トレンド分析、2018年～2030年：
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
  • ベンダー情勢
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • MDx Health
    • Myriad Genetics, Inc.
    • Abbott Laboratories
    • F. Hoffman-La Roche AG
    • Bayer AG
    • Siemens Healthcare GmbH
    • OPKO Health, Inc.
    • Genomic Health.
    • Pfizer Inc.
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Prostate Cancer Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 4 North America Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 6 U.S. Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 10 Canada Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 11 Canada Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Europe Prostate Cancer Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 14 Europe Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 15 Europe Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Germany Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 17 Germany Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 18 Germany Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 19 UK Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 20 UK Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 21 UK Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 23 France Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 24 France Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 25 Italy Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 26 Italy Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 27 Italy Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Spain Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 29 Spain Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 30 Spain Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Denmark Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 32 Denmark Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 33 Denmark Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Sweden Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 35 Sweden Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 36 Sweden Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Norway Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 38 Norway Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 39 Norway Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Prostate Cancer Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 44 China Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 45 China Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 46 China Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Japan Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 48 Japan Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 49 Japan Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 50 India Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 51 India Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 52 India Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 53 South Korea Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 54 South Korea Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 55 South Korea Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Australia Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 57 Australia Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 58 Australia Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Thailand Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 60 Thailand Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 61 Thailand Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Latin America Prostate Cancer Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 64 Latin America Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 65 Latin America Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Brazil Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 67 Brazil Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 68 Brazil Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Mexico Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 70 Mexico Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 71 Mexico Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 72 Argentina Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 73 Argentina Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 74 Argentina Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 75 MEA Prostate Cancer Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 77 MEA Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 78 MEA Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 79 South Africa Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 80 South Africa Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 81 South Africa Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 85 UAE Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 86 UAE Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 87 UAE Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Prostate Cancer Diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Prostate Cancer Diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Prostate Cancer Diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Prostate Cancer Diagnostics market: market outlook
  • Fig. 14 Prostate Cancer Diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Prostate Cancer Diagnostics market driver impact
  • Fig. 20 Prostate Cancer Diagnostics market restraint impact
  • Fig. 21 Prostate Cancer Diagnostics market strategic initiatives analysis
  • Fig. 22 Prostate Cancer Diagnostics market: Test Type movement analysis
  • Fig. 23 Prostate Cancer Diagnostics market: Test Type outlook and key takeaways
  • Fig. 24 Preliminary Tests Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 25 PSA Tests Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 26 Free PSA Test Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 27 Total PSA Test Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 28 Other Preliminary Tests Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 29 Confirmatory Tests Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 30 Pca3 Test Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 31 Trans-Rectal Ultrasound Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 32 Biopsy Test Prostate Cancer Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 33 Prostate Cancer Diagnostics Market: Type movement Analysis
  • Fig. 34 Prostate Cancer Diagnostics market: Type outlook and key takeaways
  • Fig. 35 Adenocarcinoma market estimates and forecasts, 2018 - 2030
  • Fig. 36 Interstitial Cell Carcinoma market estimates and forecasts,2018 - 2030
  • Fig. 37 Other market estimates and forecasts,2018 - 2030
  • Fig. 38 Prostate Cancer Diagnostics market: End Use movement analysis
  • Fig. 39 Prostate Cancer Diagnostics market: End Use outlook and key takeaways
  • Fig. 40 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 41 Outpatient Facilities market estimates and forecasts,2018 - 2030
  • Fig. 42 Home Care market estimates and forecasts, 2018 - 2030
  • Fig. 43 Research & Manufacturing market estimates and forecasts,2018 - 2030
  • Fig. 44 Global Prostate Cancer Diagnostics market: Regional movement analysis
  • Fig. 45 Global Prostate Cancer Diagnostics market: Regional outlook and key takeaways
  • Fig. 46 Global Prostate Cancer Diagnostics market share and leading players
  • Fig. 47 North America market share and leading players
  • Fig. 48 Europe market share and leading players
  • Fig. 49 Asia Pacific market share and leading players
  • Fig. 50 Latin America market share and leading players
  • Fig. 51 Middle East & Africa market share and leading players
  • Fig. 52 North America: SWOT
  • Fig. 53 Europe SWOT
  • Fig. 54 Asia Pacific SWOT
  • Fig. 55 Latin America SWOT
  • Fig. 56 MEA SWOT
  • Fig. 57 North America, by country
  • Fig. 58 North America
  • Fig. 59 North America market estimates and forecasts, 2018 - 2030
  • Fig. 60 U.S.
  • Fig. 61 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 62 Canada
  • Fig. 63 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 64 Europe
  • Fig. 65 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 66 UK
  • Fig. 67 UK market estimates and forecasts, 2018 - 2030
  • Fig. 68 Germany
  • Fig. 69 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 70 France
  • Fig. 71 France market estimates and forecasts, 2018 - 2030
  • Fig. 72 Italy
  • Fig. 73 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 74 Spain
  • Fig. 75 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 76 Denmark
  • Fig. 77 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 78 Sweden
  • Fig. 79 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 80 Norway
  • Fig. 81 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 82 Asia Pacific
  • Fig. 83 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 84 China
  • Fig. 85 China market estimates and forecasts, 2018 - 2030
  • Fig. 86 Japan
  • Fig. 87 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 88 India
  • Fig. 89 India market estimates and forecasts, 2018 - 2030
  • Fig. 90 Thailand
  • Fig. 91 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 92 South Korea
  • Fig. 93 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 94 Australia
  • Fig. 95 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 96 Latin America
  • Fig. 97 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 98 Brazil
  • Fig. 99 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 100 Mexico
  • Fig. 101 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 102 Argentina
  • Fig. 103 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 104 Middle East and Africa
  • Fig. 105 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 106 South Africa
  • Fig. 107 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 108 Saudi Arabia
  • Fig. 109 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 110 UAE
  • Fig. 111 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 112 Kuwait
  • Fig. 113 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 114 Market share of key market players - Prostate Cancer Diagnostics market
目次
Product Code: GVR-2-68038-548-9

Prostate Cancer Diagnostics Market Growth & Trends:

The global prostate cancer diagnostics market size is expected to reach USD 13.16 billion by 2030, expanding at a CAGR of 6.4% from 2024 to 2030,according to a new report by Grand View Research, Inc. Supportive government initiatives, increasing disease prevalence across the globe, and a rise in the prevalence of prostate cancer coupled with technological advancements in confirmatory diagnostic tests are the major drivers for this market.

A rise in favorable government initiatives to enhance research associated with a focus on effective diagnosis and treatment is expected to boost market growth during the forecast period. For instance, the National Cancer Institute initiated the study titled 'Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress' (RESPOND). This study is the largest collaboration to research the non-biological and biological factors that are associated with prostate cancer in African-American men. It was launched by the National Institute on Minority Health and NCI and Health Disparities in collaboration with the Prostate Cancer Foundation with a funding of USD 26.0 million.

Researchers from the University of Norfolk and East Anglia along with Norwich University Hospital developed a non-invasive urine test that helps in identifying men that are up to 8 times less likely to need a treatment procedure within 5 years of diagnosis. Technological advancements such as these are also anticipated to impact market potential in the near future.

Additionally, researchers at Karolinska and KTH Institute concluded that the use of artificial intelligence in spatial transcriptomics can aid in the early detection of prostate cancer, thereby, improving clinical diagnosis and treatment. Spatial transcriptomics is a method that usually combines quantitative analysis of active genes and their histology and can aid in effective disease diagnosis.

Prostate Cancer Diagnostics Market Report Highlights:

  • Confirmatory tests held the largest market share in 2023. The segment holds largest market share by 66.4%. Confirmatory tests include the PCA3 test, Transrectal Ultrasound (TRUS), and biopsy of the affected portion
  • Based on end use, the market is segmented into hospitals, outpatient facilities, home care, and research & manufacturing. In 2023, the Outpatient Facilities segment dominated the market. Outpatient Facilities have revolutionized and developed more comfortable consulting and treatment systems with the acquisition and experience of the licensed physician
  • The North American region holds the largest market share owing to rising prevalence and the rise in government initiatives to enhance diagnosis

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test Type
    • 1.2.2. Type
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test Type
    • 2.2.2. Type
    • 2.2.3. End Use
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Prostate Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of prostate cancer
      • 3.2.1.2. Increasing global geriatric population
      • 3.2.1.3. Technological advancements in the field of cancer diagnostics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of diagnostics
  • 3.3. Prostate Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Prostate Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

  • 4.1. Test Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Prostate Cancer Diagnostics Market by Test Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Preliminary Tests
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. PSA Tests
      • 4.4.1.2.1 Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Free PSA Test
      • 4.4.1.3.1 Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Total PSA Test
      • 4.4.1.4.1 Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Other Preliminary Tests
      • 4.4.1.5.1 Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Confirmatory Tests
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Pca3 Test
      • 4.4.2.2.1 Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Trans-Rectal Ultrasound
      • 4.4.2.3.1 Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.4. Biopsy Test
      • 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Prostate Cancer Diagnostics Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Prostate Cancer Diagnostics Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Adenocarcinoma
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Interstitial Cell Carcinoma
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Other
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Prostate Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. End-use Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Prostate Cancer Diagnostics Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Hospitals
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Outpatient Facilities
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Home Care
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Research & Manufacturing
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Prostate Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. MDx Health
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Test Type benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Myriad Genetics, Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Test Type benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Abbott Laboratories
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Test Type benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. F. Hoffman-La Roche AG
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Test Type benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Bayer AG
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Test Type benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Siemens Healthcare GmbH
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Test Type benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. OPKO Health, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Test Type benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Genomic Health.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Test Type benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Pfizer Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Test Type benchmarking
      • 8.3.12.4. Strategic initiatives